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Abstract
Bladder cancer (BC) is the second most common malignancy in the urologic field.
Preoperative predictive biomarkers of cancer progression and prognosis are impera‐
tive for optimizing appropriate treatment for patients with BC. The prediction of patient
outcomes before initial treatment would enable physicians to choose better modalities
and avoid unnecessary  aggressive  treatments.  In  addition,  preoperative  molecular
markers are expected to be a minimally invasive tool for predicting precise prognosis
and progression in patients with BC. The proteins secreted from the tumor cells reflect
various states of tumors in real time and at given conditions, and those expression
patterns are different from normal cell components. Approximately 20–25% of cellular
proteins are in extracellular spaces, and these proteins have important roles in invasion,
angiogenesis,  regulation  of  cell-to-cell  interactions,  and  metastasis.  It  has  been
suggested that tumor-secreting proteins are a promising source for tumor diagnostic
biomarkers. Proteomic analysis was utilized to identify the secreted proteins in sera
from patients with BC. Several biomarkers associated with BC are reviewed here.
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1. Introduction
Bladder cancer (BC) is one of the most common malignancies of the urinary tract and results in
significant  morbidity  and  mortality  worldwide.  Approximately  75–85% of  BC cases  are
diagnosed as nonmuscle-invasive bladder cancer (NMIBC) at the first diagnosis, and approxi‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
mately 70% of cases present as pTa, 20% present as pT1, and 10% present as carcinoma in situ
(CIS) lesions [1]. NMIBC has a tendency to recur (50–70%) and may progress (10–20%) to a higher
grade and/or muscle-invasive BC (MIBC) in time, which can lead to high cancer-specific mortality
[2].
Histological tumor grade is one of the clinical factors associated with outcomes of patients
with NMIBC. High-grade NMIBC generally exhibits more aggressive behavior than low-grade
NMIBC, and it increases the risk of a poorer prognosis [3, 4]. Due to the unfavorable prognosis
of high-grade NMIBC, a differential diagnosis between high-grade and low-grade NMIBC
might be crucial for more appropriate follow-up and aggressive treatment. Cystoscopy and
urine cytology are commonly used techniques for the diagnosis and surveillance of BC.
Cystoscopy can identify the most papillary and solid lesions, but this is highly invasive for the
patients; however, urine cytology is limited by examiner experience and low sensitivity. For
these reasons, some tumor markers have been investigated (e.g., BTAstat, NMP22), but their
sensitivity and specificity are limited [5] and they are unable to predict the clinical outcome of
BC patients.
Preoperative predictive biomarkers for cancer progression and prognosis are imperative for
optimizing appropriate treatment for patients with BC. The prediction of patient outcomes
before initial treatment would enable physicians to choose better modalities and avoid
unnecessary aggressive treatments [6, 7]. Various predictive models have been widely
investigated to reduce BC-related deaths. One of the challenges is precisely predicting the
pathological stage, which is a reliable and established factor connected to disease prognosis
[8, 9]. Although preoperative computed tomography and magnetic resonance imaging for BC
staging are undergoing development, their accuracy for predicting pathological stage varies
between 40% and 90% [10, 11]. To overcome these limitations, preoperative molecular markers
are expected to be a minimally invasive tool for predicting precise prognosis and progression
in patients with BC.
Numerous efforts have been made to identify tumor markers. In recent years, a vast array of
tumor antigens and their products have been identified. Hegele et al. investigated the serum
levels of carcinoembryonic antigen (CEA) and carbohydrate-antigen 19-9 (CA19-9) in patients
with BC [12]. They concluded that the serum levels of CEA and CA19-9 are associated with
tumor invasiveness and pathologic grade. Another study of the serum level of CEA, CA19-9,
and soluble cytokeratin 19 fragment (CYFRA21-1) in BC patients indicated that CYFRA21-1 is
relatively useful for monitoring BC and predicting its prognosis [13]. These serum materials
might be useful for monitoring and staging BC. However, a serum marker that can serve as a
reliable detection marker for BC has yet to be identified.
The proteins secreted from the tumor cells reflect various states of the tumor in real time and
at given conditions, and those expression patterns are different from normal cell components.
Thus, the proteins secreted into body fluids, such as serum, urine, cerebrospinal fluid, tears,
and saliva, from tumor cells and conditioned media of cultured tumor cells have been
investigated. Approximately 20–25% of cellular proteins are in extracellular spaces, and these
proteins have important roles in differentiation, invasion, metastasis, angiogenesis, and
regulation of cell-to-cell and cell-to-extracellular matrix interactions [3, 14, 15]. It has been
Role of Biomarkers in Medicine34
suggested that tumor-secreting proteins are a promising source for tumor diagnostic bio‐
markers. Proteomic analysis was utilized to identify the secreted proteins in sera from patients
with BC. Several biomarkers and their association with BC are reviewed here [4, 5, 16, 17].
2. Candidates for a serum biomarker in patients with bladder cancer
2.1. Uroplakin III
Uroplakin plays a key role in urothelial functions, including participation in the permeability
barrier, adjustment of urothelial surface area, stabilization of the urothelial surface, and
development of the urinary tract [18]. Because of their specific expression in the urothelium,
uroplakin has been investigated as a potential immunohistochemical marker for primary
lesions and for identification of the primary cancer in patients with metastases of unknown
origin [19]. The uroplakin family comprises a group of four transmembrane proteins, including
Ia (27 kDa), Ib (28 kDa), II (15 kDa), and III (47 kDa) [20]. Uroplakin III is the largest protein in
the uroplakin family and has been exclusively investigated by immunohistochemical staining.
In a previous study, the loss of uroplakin III expression in pathological specimens is associated
with biologically aggressive BC and poor prognosis for patients who underwent radical
cystectomy [3]. However, the utility of serum uroplakin III (e.g., predictive models of disease
outcome) in patients with BC is unknown.
Serum uroplakin III levels were investigated in patients with BC and healthy controls utilizing
dot blot analysis to demonstrate the role of preoperative serum uroplakin III levels as a
potential biomarker for BC (Table 1) [17]. The uroplakin III levels in serum in patients with
NMIBC, in those with MIBC, and in healthy controls were 1.3, 2.8, and 0.7, respectively. The
serum uroplakin III levels in patients with NMIBC and MIBC were significantly higher than
those in healthy controls (P = 0.04 and P < 0.001, respectively). Comparison of BC groups with
the control group yielded the area under the curve-receiver operating characteristics (AUC-
ROC) levels for NMIBC and MIBC of 0.62 and 0.88, respectively. The sensitivity and specificity
for NMIBC, using a cut-point of 2.1, were 29% and 96%, respectively. The sensitivity and
specificity for MIBC, using a cut-point of 2.0, were 67% and 96%, respectively. There was a
significantly greater increase in serum uroplakin III levels in patients with MIBC than in those
with NMIBC (P = 0.003). Preoperative serum uroplakin III levels were significantly higher in
patients with positive lymphovascular invasion and pathological grade 3 disease than in those
with negative lymphovascular invasion and grade 1 or grade 2 disease. There were no
significant differences in other factors, including gender, age, and lymph node status. Survival
analysis showed that patients with high serum uroplakin III had a significantly increased
probability of cancer-specific death (P = 0.04). However, there was no factor associated with
an increased risk for cancer-specific death in multivariate Cox proportional hazards regression
analysis. These findings suggest that serum uroplakin III is one of the candidates for a
predictive biomarker for prognosis of patients with BC.
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N of patients (%) Serum uroplakin III level P*
Median Range
Sex 0.41
Male 44 (85) 1.8 0.0–6.9
Female 8 (15) 1.7 0.02–3.2
Age (years) 0.72
<65 18 (35) 1.6 0.0–6.9
≥65 34 (65) 1.8 0.0–6.0
Pathological
stage
0.003
<pT2 28 (54) 1.3 0.66–6.0
≥pT2 24 (46) 2.8 0.0–6.9
Pathological
grade
0.005
Grade 1 or 2 27 (52) 1.3 0.0–5.4
Grade 3 25 (48) 2.5 0.25–6.9
Lymphovascular
invasion
0.02
Negative 35 (67) 1.3 0.0–6.9
Positive 17 (33) 2.5 0.66–6.0
Lymph node
metastases
0.4
Negative 46 (88) 1.7 0.0–6.9
Positive 6 (12) 2.6 0.74–5.4
*Mann-Whitney U test.
Table 1. Serum uroplakin III levels in patients with bladder cancer.
Other investigators have evaluated the role of the uroplakin family in blood samples from
patients with BC [21, 22]. Circulating uroplakin II mRNA-positive cells in blood samples were
detected using a nested reverse-transcription polymerase chain reaction assay, as reported by
Lu et al. [22]. The detection rate was associated with pathological stage, and positive rates of
uroplakin II mRNA were increased with disease extension. Li et al. [21] investigated expression
levels of uroplakin II–positive cells in sequential blood samples from patients with metastatic
BC. After chemotherapeutic treatment, patients responded well to chemotherapy and
uroplakin II–positive cells disappeared. These previous studies showed that uroplakin II in
peripheral blood might be used as a biomarker for cancer stage and treatment response.
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Although none of the biomarkers detected prognosis for patients with BC, reliable biomarkers
will lead to avoidance of unnecessary chemotherapy and radiation and will help physicians
choose intensive treatment for the appropriate patients. Expression levels of serum uroplakin
III could be used as a predictive biomarker for patients who are at increased risk for worse
prognosis. This would help physicians make decisions regarding individual treatment.
2.2. Periplakins
The plakin family mediates tissue filaments that represent the cell cytoskeleton in cell-to-cell
junctions mediated by cadherin, and it is able to withstand mechanical stimulation and provide
integrity of tissues [23, 24]. Dysfunctional plakin proteins show diverse diseases, and autoan‐
tibodies (AAb) and mutations perturb their activities with profound consequences. Seven
plakin proteins are currently reported. For example, envoplakin, desmoplakin, and periplakin
are related to desmosomes in various tissues. A proteomics technique like two-dimensional
gel electrophoresis (2-DE) plus immunoblot analysis has been demonstrated to identify tumor-
associated proteins for BC [4]. The 195-kDa membrane-associated protein periplakin is
involved in cellular movement and attachment [25]. Loss of periplakin expression determined
using immunohistochemical staining was associated with biological aggressiveness of BC [26].
In addition, the majority of BC cases showed loss or decreased expression patterns compared
with normal or benign lesions on pathological slides. Another study determined whether the
dynamics of serum periplakin would detect BC and predict the prognosis of patients with BC
(Table 2) [16].
N of patients (%) Serum periplakin levels P*
Median Range
Sex 1
Male 43 (86) 0.23 0.0–4.4
Female 7 (14) 0.32 0.0–20.5
Age (years) 0.4
<65 16 (32) 0 0.0–7.0
≥65 34 (68) 0.51 0.0–20.5
Pathological stage 0.03
<pT2 27 (54) 0 0.0–4.1
≥pT2 23 (46) 1.5 0.0–20.5
Pathological grade 0.4
Grade 1 or 2 26 (52) 0 0 0–7.9
Grade 3 24 (48) 0.98 0.0–20.5
Lymphovascular invasion 0.4
Negative 33 (67) 0.043 0.0–7.0
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N of patients (%) Serum periplakin levels P*
Median Range
Positive 17 (33) 0.74 0.0–20.5
Lymph node metastases 0.4
Negative 44 (88) 0.50 0.0–3.8
Positive 6 (12) 0.16 0.0–20.5
*Mann-Whitney U test.
Table 2. Serum periplakin levels in patients with bladder cancer.
The median levels of serum periplakin in patients with BC were significantly less than those
of healthy controls (0.3 and 5.7, respectively; P < 0.0001). The AUC-ROC level for the compar‐
ison between the BC group and the control group was 0.85. The sensitivity and specificity for
BC, using a cut-off point of 4.0, were 84% and 73%, respectively. The levels of serum periplakin
were higher in patients with MIBC than in those with NMIBC (0 and 1.5, respectively; P = 0.03).
However, serum periplakin levels were not associated with other factors, including gender,
age, pathological grade, lymphovascular invasion, and lymph node status. Survival analyses
using the log-rank test showed no significant differences in terms of progression and cancer-
specific survival. Using multivariate Cox proportional hazards regression analysis, it was
determined that none of the factors was associated with an increased risk for progression or
cancer-specific survival.
Recent studies described the biological role of periplakin in cancer. Decreased expression of
periplakin was associated with the progression of esophageal squamous cell carcinoma [27,
28]. Cyclin A2–induced upregulation of periplakin was associated with poor prognosis as well
as cisplatin resistance in endometrial cancer cells [29]. Periplakin silencing reduced migration
and attachment of pharyngeal squamous cancer cells [30]. Periplakin silencing in triple-
negative breast cancer cells increased cell growth and reduced cell motility [31]. The loss of
periplakin expression determined using immunohistochemical staining was associated with
pathological stage and cancer-specific survival in patients with BC [26]. Periplakin is impera‐
tive for maintaining epithelial cell barriers, cellular movement, and attachment in normal
physiology [23–25].
Patients with BC showed significantly decreased expression of serum periplakin protein
compared with normal controls. It may be suitable as an adjunct to urine cytology and
cystoscopy as a noninvasive diagnostic modality.
2.3. S100A6
The S100 protein family contains more than 20 low-molecular-weight Ca2+-binding proteins
[32]. Most of the genes encoding S100 proteins are located as a cluster on chromosome 1 in the
human genome [32, 33]. These proteins are localized in the cytoplasm and nucleus of a wide
range of cells and help regulate many cellular processes, such as cell-cycle progression and
differentiation [33]. Therefore, the S100 protein family is emerging as a potentially important
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group of markers in multiple types of tumors. One of these proteins, S100A6, was reported to
regulate the actin cytoskeleton function, ubiquitin ligase action, cell proliferation, and apop‐
tosis [32]. S100A6 overexpression has been frequently reported under stress conditions [34]
and in various types of cancers, including melanoma, colon, pancreatic, gastric cancer, and BC
[5].
The levels of S100A6 expression in sera of healthy controls and BC patients were investigated
[5]. There was a significant difference between BC patients and healthy controls (P = 0.001;
Figure 1). Serum S100A6 expression in NMIC patients was significantly higher than that of
healthy controls (P = 0.04). Serum S100A6 in patients with MIBC was significantly higher than
that in NMIBC patients (P = 0.004). Serum S100A6 in BC patients was associated with patho‐
logical grade (P = 0.001). However, there was no association between lymph node status and
serum S100A6. At a cut-off point of 0.5, the sensitivity and specificity of S100A6 expression as
a marker for BC were 48% and 93%, respectively. As a detection marker for MIBC, at a cut-off
point of 0.4, the sensitivity and specificity were 80% and 63%, respectively. The AUC-ROC
levels were 0.73 and 0.73, respectively.
Figure 1. Levels of serum S100A6 in healthy controls and bladder cancer patients. There was statistical significance
between groups.
S100A6, a member of the S100 family of calcium-binding proteins, is expressed in BC tissue
[35], and immunohistochemical staining of S100A6 showed localization mainly in the cyto‐
plasm of tumor cells [36]. The expression patterns of S100A2 and S100A4, also members of the
S100 family, correlated well with pathological stage and prognosis [14]. This finding demon‐
strated that only one clinical aspect represented postoperative outcomes. It is difficult to
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determine which S100 protein is better for BC in terms of biological markers; however, serum
markers are potentially useful in clinical practice both preoperatively and postoperatively. Cai
et al. reported an association between increased serum S100A6 levels and acute coronary
syndrome [37]. S100A6 levels were significantly increased and correlated with tumor necrosis
factor (TNF)-α levels in patients with coronary events. They concluded that a close relationship
exists between S100A6 and TNF-α-mediated inflammation. Another study reported the
expressions of TNF-α and pigment epithelium-derived factor (PEDF), which are highly
selective in inhibiting remodeling vessels by inducing apoptosis of endothelial cells in healthy
urothelium and in patients with urothelial carcinoma. Decreased PEDF expression and
increased TNF-α expression were identified in tumorous tissue compared with healthy
urothelium, and the authors concluded that decreased PEDF or increased TNF-α expression
is related to differentiation, invasiveness, and angiogenesis of BC [38]. In a study using
immunohistochemical staining of 83 patients who underwent radical cystectomy, univariate
and multivariate analyses showed that overall survival was significantly greater among
patients with lower S100A6 expression [36]. Although the precise mechanism underlying the
correlation of S100A6 expression with pathological stage remains to be clarified, serum S100A6
may reveal its role in the biological aggressiveness of BC.
Serum levels of S100A6 in BC patients were significantly higher than in healthy controls. In
addition, serum level of S100A6 was associated with pathological stage. By applying this serum
marker in clinical practice, patients would benefit from experiencing less invasive examina‐
tions and it would allow detection of life-threatening cancer earlier than current modalities.
3. Future Potential
BC ranks as one of the most prevalent newly diagnosed cancers. High-risk NMIBC revealed
high rates (up to 90%) of recurrence [39]. It is important to diagnose BC accurately and quickly
with the help of a simple and cost-effective method. Although histological examination
remains the gold standard, urine cytology is helpful as a noninvasive method of early diagnosis
of BC [40]. With the currently available modalities, there is no reliable biochemical or molecular
examination that can be used as a universal screening tool for BC.
Tumor-associated antigens released into the bloodstream could induce a humoral immune
response and generate AAb. The immune response to such antigens generates remarkable
biological amplification, although tumor-associated antigens are undetectable in sera during
the early stage of tumorigenesis [41]. Therefore, hundreds of tumor-associated antibodies have
been identified as potential AAb biomarkers that could be useful for cancer diagnosis [42]. In
addition, recent studies based on AAb profiling of cancer patients have suggested diagnostic
and prognostic biomarker potential of AAb [43].
Immunoblot analysis combined with 2-DE can identify tumor-associated secreted antigenic
proteins that elicit a humoral response in sera of BC patients. By comparing immunoreactive
patterns from sera of patients with high-grade and low-grade BC, tumor markers associated
with histological grade were obtained. The proteins extracted from culture supernatants of BC
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cell lines were separated by 2-DE and transferred onto the polyvinylidene difluoride mem‐
branes, and they reacted with mixed sera of patients with high-grade BC or low-grade BC.
Results indicated that serum IgG levels of anti-calreticulin (CALR) and matrix metalloprotei‐
nase (MMP)-2 AAb were significantly higher in BC patients than in normal controls (P < 0.01)
[4]. In the ROC analysis for anti-CALR AAb, the diagnostic sensitivity and specificity for BC
patients were 64% and 60%, respectively. In terms of anti-MMP AAb, sensitivity and specificity
for BC patients were 60% and 62%, respectively. The AUC-ROC levels were 0.65 and 0.59,
respectively. AAb against tumor-associated antigens have been identified in sera from patients
with various cancers, including BC [4]. The application of the humoral immune response for
the detection of cancer biomarkers has great potential [42, 43]. Furthermore, the immune
system is especially well adapted for early detection of cancer because AAb can be detected
before the appearance of other biomarkers or phenotypic alternations at an early stage of
tumorigenesis [41].
Although the prostate-specific antigen test is utilized for the detection of prostate cancer, a
diagnosis of BC still relies on imaging modality and cystoscopy because effective and simple
screening biomarkers are lacking. Further research is warranted to clarify the availability and
limits of the aforementioned serum markers in patients with BC.
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